The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 2, 2007, Pages 122-128

  Ascher Svanum, Haya ^a   Zhu, Baojin ^a   Ernst, Frank R ^a,d   Faries, Douglas E ^a   Jacobson, Jennie G ^a   Doebbeling, Caroline C ^b,c  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Premier Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; UNITED STATES;

EID: 34247187489     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.v09n0206     Document Type: Article

References (42)

1. Daumit GL, Pratt LA, Crum RM, et al. Characteristics of primary care visits for individuals with severe mental illness in a national sample. Gen Hosp Psychiatry 2002;24:391-395
2. Sokal J, Messias E, Dickerson FB, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004;192:421-427
3. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73
4. Ryan M, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289
5. Chafetz L, White MC, Collins-Bride G, et al. The poor general health of the severely mentally ill: impact of schizophrenic diagnosis. Community Ment Health J 2005;41:169-184
6. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004;65:715-720
7. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217
8. Cournos F, McKinnon K, Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry 2005;66(suppl 6):27-33
9. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-170
10. Cohen D, Dekker JJ, Peen J, et al. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur Neuropsychopharmacol 2006;16:187-194
11. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed 2004;6:5
12. Koran LM, Sheline Y, Imai K, et al. Medical disorders among patients admitted to a public-sector psychiatric inpatient unit. Psychiatr Serv 2002;53:1623-1625
13. Chwastiak L, Rosenheck R, Leslie D. Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample. Med Care 2006;44:55-61
14. Dixon LB, Kreyenbuhl JA, Dickerson FB, et al. A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatr Serv 2004;55:892-900
15. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-460
16. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26
17. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-1078
18. Smith DW. The population perspective on quality of life among Americans with diabetes. Qual Life Res 2004;13:1391-1400
19. Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8
20. Van Dorn RA, Swanson JW, Swartz MS, et al. The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. Ment Health Serv Res 2005;7:123-134
21. Swanson JW, Swartz MS, Elbogen EB, et al. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry 2004;65:1666-1673
22. Slade EP, Salkever DS, Rosenheck R, et al. Cost-sharing requirements and access to mental health care among Medicare enrollees with schizophrenia. Psychiatr Serv 2005;56:960-966
23. Skinner KM, Miller DR, Lincoln E, et al. Concordance between respondent self-reports and medical records for chronic conditions: experience from the Veterans Health Study. J Ambulatory Care Manage 2005;28:102-110
24. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
26. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398
27. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
28. Lehman AF, Fischer EP, Postrado L, et al. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull 2003;29:247-256
29. Lehman A. A quality of life interview for the chronically mentally ill. Eval Progra Plann 1988;11:51-62
30. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233
31. Mallinckrodt CH, Sanger TM, Dube S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003;53:754-760
32. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22
33. Snaith RP, Harrop FM, Newby DA, et al. Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry 1986;148:599-601
34. Druss BG, Rohrbaugh RM, Levinson CM, et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry 2001;58:861-868
35. Druss BG, Rosenheck RA, Desai MM, et al. Quality of preventive medical care for patients with mental disorders. Med Care 2002;40:129-136
36. Taylor D, Young C, Mohamed R, et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005;19:182-186
37. Gregg EW, Cadwell BL, Cheng YJ, et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the US. Diabetes Care 2004;27:2806-2812
38. Brar J, Ganguli R, Pandina G, et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66:205-212
39. Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-962
40. Hoffmann VP, Ahl J, Meyers A, et al. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry 2005;66:1576-1579
41. Krosnick A, Wilson MG. A retrospective chart review of the clinical effects of atypical antipsychotic drugs on glycemic control in institutionalized patients with schizophrenia and comorbid diabetes mellitus. Clin Ther 2005;27:320-326
42. Vreeland B, Minsky S, Menza M, et al. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003;54:1155-1157